Learn about BYETTA, the BYETTA Pen. Important Safety Information for BYETTA (exenatide) injection. Contraindications. BYETTA is contraindicated in. Exenatide (Byetta) is the first in a new class of incretin peptide mimetics .. Available at ; accessed October 15, 3. Meneilly. Exenatide (marketed as Byetta, Bydureon) is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) medication, belonging to the group of incretin.
|Published (Last):||10 March 2014|
|PDF File Size:||1.71 Mb|
|ePub File Size:||1.73 Mb|
|Price:||Free* [*Free Regsitration Required]|
Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus
The insulin lispro dose was titrated based on preprandial glucose values. It is unknown whether patients with a history of pancreatitis are at increased risk for pancreatitis while using BYETTA; consider other antidiabetic therapies for these patients. Insulin-like factor 3 Relaxin 123 Serelaxin.
Byetta is supplied for SC injection as a sterile, preserved isotonic solution in a glass cartridge that has been assembled in a pl pen. In developmental toxicity studies, pregnant animals received exenatide subcutaneously during organogenesis. When Byetta is used in combination with insulin, the dose of insulin should be evaluated. The concurrent use of Byetta with prandial insulin has not been studied and cannot be recommended.
Effects of the overdoses byeta severe nausea, severe vomiting, and rapidly declining blood glucose concentrations. There have been postmarketing reports of serious hypersensitivity reactions e.
Patients may develop antibodies to exenatide following treatment with Byetta. DeFronzo et al compared exenatide in type 2 diabetic patients being treated with metformin monotherapy in a multi-centered, randomized, triple-blinded, placebo-controlled study 6. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Welcome to BYETTA.com!
Baseline body weight across treatment arms was approximately 96 kg. Based on postmarketing data Byetta has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis.
Byetta or placebo was injected subcutaneously before the morning and evening meals. Other side effects include dizziness, headache, and feeling jittery. You may report side effects related to AstraZeneca products by clicking here.
However, in subjects with end-stage renal disease receiving dialysis, mean exenatide exposure increased by 3. Exenatide Byetta is the first in a new class of incretin peptide mimetics glucagon-like polypeptide-1 [GLP-1] receptor agonists available in the USA.
It also may increase risk of mild sulfonylurea-induced hypoglycemia. Administration of warfarin 25 mg 35 minutes after repeated doses of Byetta 5 mcg BID on days and 10 mcg BID on days in healthy volunteers delayed warfarin T max by approximately 2 hours. The three patients recovered without complication. The pain may be felt going from your abdomen through to your back. BydureonBydureon BCise.
Concurrent use with prandial insulin has not been studied and cannot be recommended. Exenatide is a amino-acid peptide ; it is a synthetic version of Exendin-4a hormone found in the saliva of the Gila monster.
Incretins, such as glucagon-like peptide-1 GLP-1enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation from the gut. If symptoms of hypersensitivity reactions occur, patients must stop taking Byetta and seek medical advice promptly [see Warnings and Precautions 5. In healthy individuals, robust insulin secretion occurs during the first 10 minutes following intravenous IV glucose administration.
If you see more than one drop:. Byetta should not be used for the treatment of type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings.
Both of the prefilled pens are a day supply of medication. The mean baseline HbA 1c values were 7. Eli Lilly has stated the drug causes an increase in thyroid problems in rats given high doses.
Mean HbA 1c values at baseline for the trials ranged from 8. Byetta improves glycemic control by reducing fasting and postprandial glucose concentrations in patients po type 2 diabetes through the actions described below.
It was approved by the Food and Drug Administration FDA in April for adjunctive glycemic control in patients with type 2 byettx mellitus who are taking metformin, a sulfonylurea, or a combination of metformin and a sulfonylurea 2.
Both Byetta 10 mcg BID and titrated lispro provided a mean reduction in HbA 1c at Week 30 that met the pre-specified non-inferiority margin of 0. Consider antidiabetic therapies other than Byetta in patients with a history of pancreatitis.